Feedback

Moderna vaccine to provide immunity to Covid-19 for at least three months

Source : 112 Ukraine

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) held a test that showed that the Moderna vaccine is able to provide immunity from Covid-19 at least for three months
16:00, 4 December 2020

Reuters

The vaccine against Covid-19 developed by Moderna might provide immunity to the disease at least for three months as The New England Journal of Medicine reported.

It is noted that researchers from the National Institute of Allergy and Infectious Diseases (NIAID) held a test that showed that the Moderna vaccine is able to provide immunity from Covid-19 at least for three months.

Related: Covid-19: Ukrainian Health Minister opens up on decision not to purchase Russian vaccine

34 volunteers of different ages participated in the trials. The scientists examined their immune response to the vaccine from the first stage of the clinical trial of the drug. According to the results of the research, the level of the antibodies after the vaccination decreased a little. However, its number remained increased three months after the receiving of the second dose of the vaccine.

The scientists stated that there is a possibility that the immune system will remember the virus. If it is subjected to its influence, the new antibodies will be produced.

Related: Health Minister reveals when Ukraine to get anti-Covid-19 vaccine

Besides, the research showed that the vaccine activated the particular type of cells that help the immune memory. To prove this fact, a number of extra tests should be held.

Moderna vaccine consists of two doses. The second – the booster dose – is provided 28 days after the first one. The vaccine is inserted in the hand where it forces the cells inside the muscles to build surface-active protein. It tricks the immune system when it faces a real virus. The price of a dose of the Moderna vaccine will vary from $25 up to $37.

Related: Vaccine against Covid-19 might be stolen, forged, - Interpol

On November 30, Moderna stated that the efficacy of its vaccine made %94.1 after the first analysis and 100% at severe cases. The new analysis from Moderna evaluated 196 confirmed Covid infections among the late-stage trial's 30,000 participants. The company said 185 cases of Covid were observed in the placebo group versus 11 cases observed in the group that received its vaccine. That resulted in an estimated vaccine efficacy of 94.1%, the company said.

Besides, during the final stage of the trial of the vaccine against coronavirus infection developed by Pfizer and BioNTech, its efficacy was increased up to 94%.

 

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more